about
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic functionUbiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancerHuman Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cellsThe use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression.Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.p53: the barrier to cancer stem cell formation.Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.Antisense approaches in prostate cancer.Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma.Tissue biomarkers for prostate cancer radiation therapy.Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistanceOral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action.Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer.Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structuresMDM2 expression and regulation in prostate cancer racial disparityNo evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interactionMDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancerAntisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.A classification framework applied to cancer gene expression profiles.Molecular mechanisms involving prostate cancer racial disparity.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Role of E3 ubiquitin ligases in lung cancer.Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland.Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses.Molecular basis for prostate cancer racial disparities.Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome.PTEN regulates Mdm2 expression through the P1 promoter.Extracellular vesicles as drivers of epithelial-mesenchymal transition and carcinogenic characteristics in normal prostate cells.Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.Human p53 and Hdm2: Cloning and Construction of Expression Plasmid
P2860
Q24338503-5932D596-5945-442E-92B2-5D2CDFE95320Q28266601-8CA497A1-9DD6-4804-A376-4CEC74738941Q28276911-338D234A-FEB3-409A-99FA-8F7055A2318FQ33238054-544F6A70-0A3E-4E0C-A700-FE007C447E5FQ34268286-9C22BCC2-33CB-4BBE-8553-EAD71F1484A1Q34406072-2D58C78A-0470-4714-B842-6D50243BB1D9Q35058579-33A58899-713D-4FBD-A420-5C2985354965Q35790875-38E5CE85-ACE2-484C-96F3-3DC5377F2D01Q36121305-E8C022E0-9AEE-45CA-848A-FDF867344C9AQ36141341-11DA731A-A89B-499E-892E-F300219619C7Q36161416-28261AFD-DCDC-4326-B556-500A87C8E3CEQ36282200-83876FA2-1558-48E9-89D7-DC0D694DC044Q36356343-2B4F035A-04ED-4004-A783-C9D41BDF8BFBQ36430872-F07A3C6A-9103-49AC-95D7-C5E0BAFA3D93Q36983259-26527609-20B7-44DE-813D-639C875DC18EQ37041767-D8418A84-EE55-4730-A8F5-0B49FC421EC2Q37195909-980B0E6A-6BB3-4A7C-8769-4AD41CC5B09DQ37286347-01069B08-18E8-472F-BD9B-1FFF7D56CEECQ37362527-69E9B0B0-9789-45E2-8278-186D3F70CDDAQ37389886-EC40F4E5-D4F1-42F1-ABF2-06FBA2A0A61BQ37389892-27699EE3-9315-4E35-8FFB-AABC2E61B43FQ37389921-DEF891C8-529D-45DE-B4A9-4AC6908BF48BQ37416138-21BB4899-9B68-4E04-8888-E85B6A528D23Q37418937-126424BE-DEC6-4AEB-AFC6-0101D0EB21D9Q37575815-EA15B745-420B-417B-804C-1F9258CFBCB4Q38128316-71D8B5CB-8923-4298-8763-825E6C7BC6F0Q38348824-5BD3B3BC-7888-41A6-9DC1-DA25C9D60358Q39922379-F31A8246-3484-4A51-AF75-09C2934D3E86Q40618953-07304DA3-1FE4-4C48-9DEC-D7EAC366BA3DQ41334556-09212F6B-DE7A-4ABF-96C5-DF4D5717F27BQ43882042-6EC987CB-FA98-4320-9044-101C7232AC11Q44848220-E91176E4-585A-43FE-8EBA-54D5E1DB2AA1Q47778400-E256C2E1-364F-4134-8D0C-308471EDF86FQ49787526-C9942451-472D-410E-88CE-48E203EB428BQ53537207-D591ED92-9F60-4511-9955-1221F6B1E986Q58131437-A4FACF08-846E-4EA6-A3D0-7E13886FA2A1
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Abnormal expression of MDM2 in prostate carcinoma.
@en
Abnormal expression of MDM2 in prostate carcinoma.
@nl
type
label
Abnormal expression of MDM2 in prostate carcinoma.
@en
Abnormal expression of MDM2 in prostate carcinoma.
@nl
prefLabel
Abnormal expression of MDM2 in prostate carcinoma.
@en
Abnormal expression of MDM2 in prostate carcinoma.
@nl
P2093
P2860
P1433
P1476
Abnormal expression of MDM2 in prostate carcinoma.
@en
P2093
A Nesrallah
C M Carvalho
L H Camara-Lopes
L J Nesrallah
M F Franco
M I Meirelles
R G Bevilacqua
P2860
P2888
P304
P356
10.1038/MODPATHOL.3880330
P577
2001-05-01T00:00:00Z